Certified by Founder Lodge
Sofinnova Partners
France - Paris, Ile-de-France
INVESTOR
1 Disclosed Funding Rounds $31,300,000
27 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a tea
Company | Date | Round | Raised |
---|---|---|---|
Moon Surgical | June, 30 ,2022 | Series A | $31,300,000 |
Mediar Therapeutics | March, 15 ,2023 | Unknown | $105,000,000 |
deepc | March, 31 ,2023 | Series A | $13,062,000 |
BioCorteX | March, 31 ,2023 | Seed | $5,000,000 |
Kiro | April, 03 ,2023 | Series A | $14,955,000 |
Werewool | May, 12 ,2023 | Seed | $3,700,000 |
TISSIUM | May, 23 ,2023 | Series D | $50,000,000 |
BrightHeart | June, 01 ,2023 | Seed | $2,151,000 |
AAVantgarde Bio | June, 07 ,2023 | Series A | $65,333,745 |
Mozart Therapeutics, Inc | June, 08 ,2023 | Series A | $25,000,000 |
Gradient Denervation Technologies | September, 08 ,2023 | Series A | $15,015,000 |
Mironid® Limited | September, 14 ,2023 | Series A | |
Sitryx | September, 28 ,2023 | Unknown | $39,500,000 |
Bon Vivant | October, 13 ,2023 | Seed | $15,800,000 |
Betteromics | October, 27 ,2023 | Series A | $20,000,000 |
l'école AI | October, 27 ,2023 | Seed | $3,000,000 |
T-Therapeutics Ltd | November, 16 ,2023 | Series A | $59,707,000 |
Freya Biosciences | December, 13 ,2023 | Series A | $38,000,000 |
DISCO Pharmaceuticals GmbH | January, 17 ,2024 | Seed | $21,727,000 |
Bioptimus | February, 21 ,2024 | Seed | $35,000,000 |
Mission Therapeutics | March, 15 ,2024 | Unknown | $32,101,650 |
Cure51 | March, 20 ,2024 | Seed | $16,260,975 |
May Health | May, 14 ,2024 | Series B | $25,000,000 |
Myricx Bio | July, 09 ,2024 | Series A | $115,246,800 |
Micropep Technologies | July, 26 ,2024 | Series B | $29,000,000 |
F2G | September, 13 ,2024 | Unknown | $100,000,000 |
Genespire | September, 26 ,2024 | Series B | $51,969,485 |